Literature DB >> 10096149

Pheochromocytoma: evaluation, diagnosis, and treatment.

M M Walther1, H R Keiser, W M Linehan.   

Abstract

Pheochromocytoma is a catecholamine-producing tumor of the sympathetic nervous system. Signs and symptoms are generally related to catecholamine excess; these include hypertension, sweating, palpitatione, headaches, and anxiety attacks. Abdominal imaging and 24-h urine collection for catecholamines are usually be sufficient for diagnosis. Catecholamine blockade with phenoxybenzamine and metyrosine generally ameliorates symptoms and is necessary to prevent hypertensive crisis during surgery. Standard treatment is laparoscopic adrenalectomy, although partial adrenalectomy is gaining enthusiastic support in familial forms of pheochromocytoma. Pheochromocytomas have been estimated to be present in approximately 0.3% of patients undergoing evaluation for secondary causes of hypertension [41]. Pheochromocytomas are usually curable if diagnosed and treated properly, but they can be fatal if they are not diagnosed or are managed inappropriately. Autopsy series suggest that many pheochromocytomas are not clinically suspected and that the undiagnosed tumor can be associated with morbid consequences [42].

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096149     DOI: 10.1007/s003450050102

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  26 in total

1.  Outcomes and timing for intervention of partial adrenalectomy in patients with a solitary adrenal remnant and history of bilateral phaeochromocytomas.

Authors:  Thomas H Sanford; Benjamin Barckley Storey; William Marston Linehan; Craig A Rogers; Peter A Pinto; Gennady Bratslavsky
Journal:  BJU Int       Date:  2010-08-19       Impact factor: 5.588

2.  Head docking for single stage robotic cortical sparing adrenalectomy for bilateral pheochromocytoma.

Authors:  Fouad Aoun; Alexandre Peltier; Roland van Velthoven
Journal:  J Robot Surg       Date:  2014-09-04

3.  Perioperative, functional, and oncologic outcomes of partial adrenalectomy for multiple ipsilateral pheochromocytomas.

Authors:  Gopal N Gupta; Jonas S Benson; Michael J Ross; Vani S Sundaram; Kelly Y Lin; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky
Journal:  J Endourol       Date:  2013-10-23       Impact factor: 2.942

4.  Appropriate premedication risk reduction during adrenal ablation.

Authors:  Deepak Sudheendra; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2006-08       Impact factor: 3.464

5.  Detecting pheochromocytoma: defining the most sensitive test.

Authors:  Ulrich Guller; Joe Turek; Steve Eubanks; Elizabeth R Delong; Daniel Oertli; Jerome M Feldman
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

6.  Organ-sparing procedures in GU cancer: part 1-organ-sparing procedures in renal and adrenal tumors: a systematic review.

Authors:  Raouf Seyam; Mahmoud I Khalil; Mohamed H Kamel; Waleed M Altaweel; Rodney Davis; Nabil K Bissada
Journal:  Int Urol Nephrol       Date:  2019-01-08       Impact factor: 2.370

7.  Routine genetic screening with a multi-gene panel in patients with pheochromocytomas.

Authors:  Emilia Sbardella; Treena Cranston; Andrea M Isidori; Brian Shine; Aparna Pal; Bahram Jafar-Mohammadi; Greg Sadler; Radu Mihai; Ashley B Grossman
Journal:  Endocrine       Date:  2017-05-05       Impact factor: 3.633

8.  Laparoscopic bilateral cortical-sparing adrenalectomy for pheochromocytoma.

Authors:  Benjamin R Biteman; James A Randall; Fred Brody
Journal:  Surg Endosc       Date:  2016-05-13       Impact factor: 4.584

9.  Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma.

Authors:  Max A Cayo; Ashley K Cayo; Sarah M Jarjour; Herbert Chen
Journal:  Am J Transl Res       Date:  2009-01-31       Impact factor: 4.060

10.  Determination of free catecholamines in urine by tandem affinity/ion-pair chromatography and flow injection analysis.

Authors:  David H Thomas; Jay D Taylor; Omar S Barnaby; David S Hage
Journal:  Clin Chim Acta       Date:  2008-08-22       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.